As filed with the Securities and Exchange Commission on February 19, 2026 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 20-F _____________________________________ (Mark one) o REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2025 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXC ...

Core Insights - Royal Philips published its Annual Report 2025, which will be discussed at the Annual General Meeting of Shareholders on May 8, 2026 [1] - The report has been filed with the Netherlands Authority for the Financial Markets in European Single Electronic Format and is expected to be filed with the U.S. Securities and Exchange Commission [2] - The Annual Report 2025 is accessible to shareholders and interested parties online, with printed copies available upon request [3] Company Overview - Royal Philips is a leading health technology company focused on improving health and well-being through innovation [4] - The company specializes in diagnostic imaging, ultrasound, image-guided therapy, monitoring, and personal health solutions, employing approximately 64,800 people and generating sales of EUR 18 billion in 2025 [5]

Core Insights - Royal Philips has launched the InkSpace Imaging Snuggle™ pediatric body array coil for its 3.0T MRI systems, aimed at enhancing comfort for pediatric patients and improving imaging efficiency for clinicians [1][4]. Group 1: Product Features - The Snuggle coil is designed specifically for pediatric patients, featuring a light, blanket-like design that wraps gently around the child, making MRI exams less intimidating [2]. - Its high-density array and flexible structure enable sharp, high-resolution images, allowing for more efficient exams across various pediatric anatomies, which can reduce the need for additional imaging or follow-up procedures [3]. Group 2: Collaboration and Development - The collaboration between Philips and InkSpace Imaging focuses on pediatric design, combining Philips' MRI leadership with InkSpace Imaging's expertise to create a child-friendly alternative to traditional rigid devices [4]. - The Snuggle coil has been cleared through the U.S. FDA 510(k) process, indicating its safety and effectiveness for use in pediatric imaging [4]. Group 3: Market Availability and Future Plans - The Snuggle pediatric coil is currently available in the United States, with plans for rollout to additional regions in the future [5]. - Philips and InkSpace Imaging are exploring further opportunities to expand coil technology that emphasizes comfort and efficiency, aiming to support healthcare professionals and families [5]. Group 4: Company Overview - Royal Philips is a leading health technology company with a focus on improving health and well-being through innovation, generating sales of EUR 18 billion in 2025 and employing approximately 64,800 people globally [7].

Core Insights - Koninklijke Philips (PHG) reported a fourth-quarter 2025 earnings of €0.41 per share, recovering from a loss of €0.35 per share in the same quarter last year [1] - The company's sales increased by 1.1% year-over-year to €5.09 billion, with comparable sales rising by 7% across all segments [1][2] - The company anticipates 3%-4.5% comparable sales growth and an adjusted EBITA margin between 12.5% and 13% for 2026 [10] Sales Performance - Comparable order intake increased by 7% year-over-year in the fourth quarter, with growth geographies showing a 15% increase, primarily driven by Personal Health [2] - Sales in Mature geographies grew by 4%, mainly due to strong contributions from North America and Connected Care [2] - Personal Health revenues grew by 9% year-over-year to €1.11 billion, with comparable sales increasing by 14% [4] Segment Analysis - Diagnosis & Treatment revenues declined by 2% year-over-year to €2.40 billion, although comparable sales increased by 4% [3] - Connected Care revenues remained stable at €1.42 billion year-over-year, with comparable sales up by 7% [3] - Other segment sales amounted to €155 million, reflecting a 2.6% year-over-year increase [4] Financial Metrics - Gross margin contracted by 600 basis points to 44.9% year-over-year [5] - Adjusted EBITA increased by 13.4% year-over-year to €770 million, with an EBITA margin expanding by 160 basis points to 15.1% [6] - Free cash flow was reported at €1.2 billion, compared to €1.28 billion in the year-ago quarter [9] Balance Sheet Overview - As of December 31, 2025, cash and cash equivalents were €2.40 billion, up from €1.91 billion as of September 30, 2025 [9] - Total debt decreased to €8.084 billion from €8.385 billion as of September 30, 2025 [9] - Operating cash flow was €1.39 billion, slightly down from €1.45 billion in the previous year [9]

Philips Says The Turnaround Is Real And The Market Believes It - Moby THE GIST Philips delivered the kind of quarter that shifts the conversation from remediation to momentum. Orders rose, sales accelerated, margins expanded, and cash flow landed with confidence. The Respironics overhang still matters, but investors are increasingly treating Philips as a functioning medtech operator with improving fundamentals and a clearer runway. WHAT HAPPENED Philips reported 2025 group sales of €17.8 billion (about $ ...

Group 1 - The article does not contain any relevant content regarding company or industry insights [1]

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN ISSUER Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 February 10, 2026 KONINKLIJKE PHILIPS N.V. (Exact name of registrant as specified in its charter) Royal Philips (Translation of registrant's name into English) The Netherlands (Jurisdiction of incorporation or organization) Prinses Irenestraat 59, 1077 WV Amsterdam, The Netherlands (Address of principal executive offices) Indicate by check mark ...

Philips Capital Markets Day 2026 Summary Company Overview - **Company**: Koninklijke Philips (NYSE:PHG) - **Industry**: Health Technology - **Focus**: Innovation in health technology, particularly in diagnosis, treatment, connected care, and personal health Key Points and Arguments Company Strategy and Vision - Philips aims to drive profitable growth and deliver sustainable value through innovation and improved operational performance [3][4][5] - The company has improved its culture, team, and business fundamentals over the past three years, positioning itself for growth acceleration [4][5][10] - Philips has a clear ambition to improve the lives of 2.5 billion people by 2030, building on the 2 billion lives improved by 2025 [8] Market Position and Leadership - Philips holds leading positions in various segments: - Number one in catheterization lab systems, interventional cardiology, cardiac ultrasound, grooming, and medical device integration [3] - Top three in diagnostic imaging and number two in oral health care and sleep and respiratory care [3] - The company has a global footprint with over 2.5 million systems installed, reaching 80% of top hospitals worldwide [19] Financial Performance and Targets - Philips aims for mid-single-digit compound annual growth rate (CAGR) and mid-teens margins by 2028, with strong cash generation of EUR 4.5 billion to EUR 5 billion over the planned period [19][41] - The company has expanded its margins by nearly 500 basis points to over 12% and targets mid-teens margins in the next three years [45] - Cash flow targets include EUR 1.3 billion to EUR 1.5 billion in 2026 and EUR 4.5 billion to EUR 5 billion cumulatively over the planned period [46] Innovation and Product Development - Philips has shifted to a business-led innovation model, focusing on customer needs and accelerating the speed of innovation [12][34] - The company has launched several groundbreaking products, including the world's first helium-free 3T MRI and advancements in ultrasound technology [25][34] - AI and data integration are central to Philips' innovation strategy, enhancing clinical decision-making and operational efficiency [17][36] Operational Improvements - Philips has simplified its operations, reducing overlapping quality management systems by over 75% and improving customer fill rates by more than 20% [14][15] - The company has implemented a decentralized decision-making model, enhancing agility and responsiveness to market demands [15] - A productivity program aims to deliver an additional EUR 1.5 billion in savings over the next three years, focusing on cost competitiveness and lean operations [59][60] Market Dynamics and Growth Opportunities - The healthcare market is projected to grow at 3%-5% annually, driven by an aging population and increasing chronic disease prevalence [16][17] - There is a widening gap between the demand for healthcare services and supply, presenting significant innovation opportunities for Philips [16] - North America is identified as a key growth engine, with double-digit growth observed in 2025 [32] Challenges and Risks - Philips acknowledges the uncertain macro environment, including potential impacts from tariffs and ongoing litigation related to the Respironics recall [46][42] - The company is committed to navigating these challenges while maintaining focus on its strategic goals [42] Conclusion - Philips is positioned for a strong future with a clear strategy focused on innovation, operational excellence, and market leadership in health technology [43][44] - The company emphasizes its commitment to delivering better care for more people while driving profitable growth and creating sustainable value [42][43]

Driving profitable growth to deliver sustainable value February 10, 2026 Capital Markets Day Roy Jakobs, Chief Executive Officer Important information Forward-looking statements and other important information This document and the related oral presentation, including responses to questions following the presentation, contain certain forward-looking statements with respect to the financial condition, results of operations and business of Philips and certain of the plans and objectives of Philips with respec ...

Financial Data and Key Metrics Changes - Order intake increased by 7% in Q4 2025, reflecting sustained improvement over the past year, with comparable sales growth also at 7% year-on-year [5][6] - Adjusted EBITDA margin improved by 160 basis points to 50.1% in Q4, and for the full year, it reached 12.3%, exceeding the outlook despite tariff impacts [5][6][21] - Net income rose to EUR 397 million in Q4, primarily due to improved operational income and lower tax charges, with adjusted diluted earnings per share increasing by 20% year-on-year [24] Business Line Data and Key Metrics Changes - In Diagnosis and Treatment (D&T), comparable sales grew by 4% in Q4, with Image-Guided Therapy achieving double-digit growth, while Precision Diagnosis remained flat [17] - Connected Care delivered 7% comparable sales growth in Q4, driven by double-digit growth in monitoring solutions [18] - Personal Health saw a 14% growth in Q4, supported by strong demand across various product categories, particularly in grooming and beauty [19] Market Data and Key Metrics Changes - North America continued to be the strongest growth driver, with sustained double-digit order intake growth [7][14] - In China, tender activity increased, but the market remains cautious due to longer processing times and tougher competition [14][15] - Europe showed stable capital spending, while select international regions increased healthcare investments, particularly in Indonesia and India [15] Company Strategy and Development Direction - The company is transitioning to a focus on profitable growth acceleration, targeting mid-single-digit sales CAGR and mid-teens margins by 2028 [6][11] - A multi-year roadmap centered on AI-enabled, patient-centric innovations is being executed, with significant product launches planned [10][19] - The company aims to enhance patient impact and quality while simplifying operations and strengthening supply chain resilience [12][13] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in entering 2026 with strong order intake momentum and a robust innovation pipeline, despite ongoing tariff challenges [26][81] - The outlook for 2026 includes expected comparable sales growth of 3%-4.5%, with a focus on North America and international regions [16][26] - Management remains cautious about the near-term outlook for China while recognizing its long-term growth potential [14][66] Other Important Information - The company completed the sale of its emergency care business in Q4 as part of its portfolio simplification strategy [19] - A new EUR 1.5 billion productivity program is being launched for the 2026-2028 period to drive further operational improvements [29] Q&A Session Summary Question: Insights on gross margin improvement and order intake for D&T - Management noted that gross margin improvement is driven by innovation and productivity, with continued margin expansion expected despite tariff impacts [34][35] - Order intake for D&T was 5%, with strong contributions from Image-Guided Therapy and ultrasound innovations [37][38] Question: Buffers in the 2026 guidance and margin expectations - Management acknowledged the need for diligence in execution and emphasized that growth will be a significant contributor to margin improvement [41][42] Question: Performance of Precision Diagnosis and Q1 growth phasing - Precision Diagnosis saw stable sales, with expectations for improved momentum in 2026 due to new innovations [49][50] - Q1 is expected to start at the lower end of the growth range due to seasonality and tariff impacts [50][51] Question: Drivers of personal health performance and Section 232 investigation - Strong personal health performance was attributed to market share gains and healthy sell-out trends, with inventory levels now aligned with market averages [56][57] - The Section 232 investigation is ongoing, with potential implications for tariffs, but no definitive outcomes have been shared [58][59] Question: Outlook for China and margin dynamics in personal health - Management remains cautious about the health system side in China while expecting some improvement in personal health sales [66] - The strong margin in personal health is driven by innovation, commercial execution, and productivity improvements [67][68]